April 2017—Sarah Cannon, the cancer institute of Hospital Corporation of America, announced that Genospace LLC, a cloud-based software company focused on advancing personalized medicine, will merge with its organization and become a wholly owned subsidiary. By joining forces, Sarah Cannon and Genospace will harness and use molecular profiling data to more effectively match cancer patients to cutting-edge therapies in clinical trials.
Genospace, which will remain based in Cambridge, Mass., is leading the development and enhancement of a cloud-based system that enables analysis of disparate data from clinical and laboratory sources across patient populations.
Through the collaboration, the genomics data technology will be integrated into Sarah Cannon’s network of oncology programs across the United States and United Kingdom.
Sarah Cannon, 615-329-7274